TOKYO, May 12 (Pulse News Wire) – StemRIM Inc. (4599.T) disclosed today that Shionogi & Co.
Ltd. has outlined future research and development schedules for the regenerative medicine drug Leudasemotide (HMGB11). Currently, Shionogi is conducting additional Phase II clinical trials targeting nutritional epidermolysis bullosa and a global late-stage Phase II trial focusing on acute ischemic stroke.
For the nutritional epidermolysis bullosa trial, interim results are expected by September 2026, followed by a domestic marketing application submission during the second half of 2026, with potential market launch planned for April 2027. For the acute ischemic stroke trial, interim results are anticipated by September 2026, with a projected market entry timeframe spanning April 2028 to March 2031. Detailed information can be found in Shionogi's May 12, 2026, annual financial statement.
StemRIM will continue to update stakeholders promptly upon receiving further developments in the ongoing trials.
🟢 Confidence: High AI-translated content.